SEARCH:   Advanced

Blood, 16 July 2009, Vol. 114, No. 3, pp. 522-525. Prepublished online as a Blood First Edition Paper on March 30, 2009; DOI 10.1182/blood-2008-12-193458. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-12-193458v1 114/3/522    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Reece, D. Articles by Bahlis, N. J. PubMed PubMed Citation Articles by Reece, D. Articles by Bahlis, N. J. Related Collections Lymphoid Neoplasia Brief Reports Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13 Donna Reece1, Kevin W. Song2, Tommy Fu3, Birgitte Roland4, Hong Chang1, Douglas E. Horsman5, Adnan Mansoor6, Christine Chen1, Esther Masih-Khan1, Young Trieu1, Helene Bruyere7, Douglas A. Stewart8, and Nizar J. Bahlis8 1 Division of Oncology, Princess Margaret Hospital, Toronto, ON; 2 Division of Hematology, Vancouver General Hospital, Vancouver, BC; 3 Celgene Corporation, Summit, NJ; 4 Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB; 5 Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC; 6 Division of Hematology and Transfusion Medicine, Calgary Laboratory Services, Calgary, AB; 7 Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, BC; and 8 Division of Hematology and Bone Marrow Transplant, University of Calgary, Calgary, AB Although the combination of lenalidomide and dexamethasone is effective therapy for patients with relapsed/refractory multiple myeloma, the influence of high-risk cytogenetic abnormalities on outcomes is unknown. This subanalysis of a large, open-label study investigated the effects of the most common unfavorable cytogenetic abnormalities detected by fluorescence in situ hybridization, del(13q), t(4;14), and del(17p13), in 130 evaluable patients treated with this regimen. Whereas patients with either del(13q) or t(4;14) experienced a median time to progression and overall survival comparable with those without these cytogenetic abnormalities, patients with del(17p13) had a significantly worse outcome, with a median time to progression of 2.22 months (hazard ratio, 2.82; P < .001) and median overall survival of 4.67 months (hazard ratio, 3.23; P < .001). Improved therapeutic strategies are required for this subgroup of patients. This study was registered at www.ClinicalTrials.gov as #NCT00179647 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Risky business in myeloma Sagar Lonial Blood 2009 114: 496-497. [Full Text] [PDF] This article has been cited by other articles: S. Lonial Risky business in myeloma Blood, July 16, 2009; 114(3): 496 - 497. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020